{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-047769","form_type":"8-K","ticker":"AARD","cik":"0001774857","company_name":"Aardvark Therapeutics, Inc.","filed_at":"2025-03-31T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.812381+00:00","generated_at":"2026-05-24T02:05:37.714772+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Aardvark Therapeutics reports FY 2024 net loss $20.6M; advances ARD-101 Phase 3 PWS trial","bullets":["Net loss $20.6M in 2024 vs $7.2M in 2023; R&D expenses $17.4M (up $12.9M YoY).","Cash, equivalents, and ST investments $73.7M at Dec 31, 2024; plus $97.9M IPO gross proceeds in Feb 2025.","ARD-101 Phase 2 PWS data: up to 16-point HQ-CT reduction in hyperphagia; body fat decreased ~1.5%, lean muscle increased >2%.","Phase 3 HERO trial topline data for PWS expected early 2026; Phase 2 HONOR (hypothalamic obesity) and EMPOWER (obesity/ARD-201 combo) expected H2 2025.","Appointed Manasi Sinha Jaiman as CMO; added Roy D. Baynes and Susan E. Graf to Board."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-047769","json":"https://secwatch.observer/filing/0000950170-25-047769.json","markdown":"https://secwatch.observer/filing/0000950170-25-047769.md","text":"https://secwatch.observer/filing/0000950170-25-047769.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1774857/000095017025047769/0000950170-25-047769-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1774857/000095017025047769/ck0001774857-20250331.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-24T02:05:37.714772+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}